• This study investigated the expression of CD55 and CD59 on red blood cells (RBCs) in stored blood.
Introduction
Packed red blood cells (PRBCs) are the most commonly transfused blood component and can be lifesaving in all age groups. It has become a daily routine to use blood transfusion for treatment of patients, and the storage of RBCs has made this possible. Current blood banking guidelines permit the storage of human RBCs for up to 42 days before clinical use [1] . This practice is based on empirical data indicating that RBCs retain sufficient integrity for transfusion efficacy during this period (defined by the Food and Drug Administration as 75% recovery 24 h after transfusion) [2, 3] . Twenty-four hours after transfusion, RBC survival was intended as a biological marker of corpuscular integrity in a manner analogous to increases in hemoglobin rather than as a measure of clinical benefit [4] .
During ex vivo storage, RBCs intended for transfusion undergo progressive changes affecting their survival and function. They undergo metabolic and structural changes during storage, collectively referred to as the "storage lesion." Principal metabolic changes over time include declining pH, reduced concentrations of ATP (adenosine 5′-triphosphate) and 2,3-DPG (diphosphoglycerate), and accumulation of extracellular potassium. Structural changes include membrane loss and the associated changes in RBC shape and rheology [5] .
Once administered, RBCs circulate continuously in intimate contact with complement proteins, and one factor that could influence their posttransfusion survival is interaction with autologous complement in the recipient. Complement-mediated RBC lysis is normally prevented by the action of surface complement regulatory proteins, including decay-accelerating factor (DAF, CD55) and membrane inhibitor of reactive lysis (MIRL, CD59) [6, 7] . They are glycosyl-phosphatidyl inositols (GPIs) anchored to the RBC cell surface [8] . Their regulatory function is mediated through the inhibition of C3 convertase formation by CD55, and the prevention of terminal polymerization of the membrane attack complex by CD59 [9] . CD55 and CD59 deficiencies have been considered to be responsible for complement-mediated lysis of affected RBCs from patients with the acquired condition paroxysmal nocturnal hemoglobinuria [10, 11] ; however, it has been shown that CD55 is not necessary for normal resistance to complement-mediated lysis, as individuals whose RBCs do not express CD55 (Inab phenotype) do not have abnormal sensitivity to complement [12] .
Long et al. [13] have shown that surface levels of CD55 and CD59 on RBCs decline gradually during 42 days of storage; however, studies linking the efficacy of RBC transfusion to storage duration have not considered the expression levels of CD55 and CD59 as a variable that may modulate the effect of transfusion. The objective of this study was to ascertain whether the expression of CD55 and CD59 is altered on stored RBCs from Arab donors.
Materials and Methods

Sample Collection
Blood samples from PRBC units from Arab donors stored in the blood bank at the Amiri Hospital were obtained from segments attached to each unit from donors who were not known to have hematologic abnormalities; they met all routine requirements for blood donation. Blood was leukodepleted and stored at 4 ° C in SAGM (saline-adenine-glucose-mannitol)-containing units according to the standard method [1] . Blood samples were obtained from PRBC units divided into 3 groups according to the following storage time frames: group 1, within the first 2 weeks of blood collection from donors; group 2, within the second 2 weeks of blood collection from donors; and group 3, within the third 2 weeks of blood collection from donors (i.e., within 2 weeks before the expiry date of the unit). Fresh, nonstored blood samples from 56 age-and sex-matched Arab healthy controls were obtained, processed, and analyzed for the expression of CD55 and CD59 within 8 h of collection.
Flow-Cytometric Analysis of CD55 and CD59 on RBCs
Blood samples were collected from segments attached to the PRBC units and processed on the day of collection. An indirect immunofluorescence method was performed as described in the package insert of the REDQUANT CD55/CD59 kit (Biocytex, Marseille, France). The kit contains monoclonal antibodies to CD55 (clone 29D9) and CD59 (clone 2.24), fluorescein isothiocyanate conjugated goat anti-mouse Ig (FITC reagent), precalibrated µ-beads for CD55 analysis and µ-beads for CD59 analysis on RBCs, and specific buffer. Briefly, 20 µL of diluted blood sample (1: 150) were incubated with 20 µL of antibodies to CD55 or CD59 for 10 min at room temperature. Two additional test tubes were added to each series, containing 40 µL of precalibrated µ-beads, respectively. Test tubes containing stained whole blood and beads were incubated with 20 µL FITC reagent for additional 10 min. After the staining procedure, samples were diluted with buffer (2 mL) and stored at 4 ° C for up to 4 h until measurement.
RBCs were evaluated for CD55 and CD59 expression using the REDQUANT kits according to manufacturer's instructions with the Cytomics FC 500 flow cytometer (Beckman Coulter, Inc., Brea, CA, USA). RBCs were gated on the basis of their forward and side scatter characteristics with the use of logarithmic amplification, and 10,000 events were analyzed for each antibody. The geometric mean fluorescent intensity (MFI) was used to quantitate the level of CD55 and CD59 expression. A cutoff for positive and negative cells was determined using the included calibrated bead with a lotspecific multiplier. Cells falling below this predetermined cutoff were considered abnormal. More than 3% of abnormal cells are required for an abnormal test result for a particular RBC marker.
Statistical Analyses
Statistical data are presented as medians and 25th and 75th percentiles, as applicable. Associations between 2 or more independent groups were compared using either the χ 2 test or Fisher's exact test, as appropriate. A value of p ≤ 0.05 was considered statistically significant.
Data were analyzed using IBM SPSS, version 23 (IBM, Armonk, NY, USA). Quantitative variables were analyzed using descriptive statistics, including measures of location where means are reported with standard deviations and medians are reported with their interquartile ranges (25th and 75th percentiles) for paramet- ric and nonparametric variables, respectively. Parametric and nonparametric measures of comparison were used for symmetrical and skewed variables, respectively. A value of p < 0.05 (two tailed) was considered statistically significant. (Fig. 2) .
Results
Data of Tested Blood Units
Analysis of CD55 and CD59 on RBCs from PRBC Units in Different Storage Age Groups
The proportions of CD55-and CD59-deficient RBCs from PRBC units did not significantly differ among the 3 age groups of stored RBC ( Table 1 ). The MFI of CD55 expression on RBCs from PRBC units did not significantly differ among these 3 groups; however, there was a statistically significant time-dependent decline in MFI of CD59 expression on RBCs from PRBC units among the groups with stored RBC, specifically between group 1 and groups 2 and 3. The difference in MFI of CD59 between healthy controls and group 1 was not statistically significant (Table 1 ; Fig. 3 ).
Discussion
Time-dependent changes, also known as storage lesion, reflect the deterioration in RBCs with storage. Many of the reported changes affect function and viability; however, information on structural time-dependent changes affecting RBC membrane proteins in stored blood is limited, and focused on vesiculation and the formation of microvesicles [14] [15] [16] . This study was aimed at examining the pattern of CD55 and CD59 expression on stored RBCs in PRBC units. As expected, the level of CD59 in stored RBCs in PRBC units was lower than that in fresh samples from healthy controls; however, although there was no statistically significant difference in the level of CD59 expression between stored RBCs and those from healthy controls, the biological significance of this difference needs to be further investigated. Interestingly, the MFI of CD55 expression on RBCs from stored blood did not significantly differ from that on RBCs from healthy controls. Unlike circulating blood, RBCs are stored at 2-6 ° C and diluted in a nonphysiological buffering system, which changes over time with respect to pH and ionic strength; this leads to the accumulation of other bioactive substances such as histamine, lipids, cytokines, and fragments of cellular membranes [17] [18] [19] . These factors might play a role in the changes in CD55 and CD59 expression observed in our study. Unexpectedly, however, our data showed a trend to a gradual decline in CD59 expression, but not CD55 expression, on RBCs from PRBC units during the storage period of 42 days, as evidenced by the statistically significant reduction in MFI of CD59 compared to CD55. Previous studies have shown conflicting findings. Our study did not reproduce the findings of Long et al. [13] , who showed that both CD55 and CD59 molecules are lost during RBC storage, although they were also able to demonstrate a similar preferential decline in the level of CD59 expression compared to CD55 expression. Furthermore, in contrast to our study, Kamhieh-Milz et al. [20] and Freitas Leal et al. [21] showed significant loss of CD55, but not CD59, expression in stored RBCs. The discrepancy in the reported results could be attributed to several factors, including the use of different additive storage solutions, the use of different methodologies, and differences in the number of samples studied and their leukodepletion status, and the gating strategy used for flow-cytometric RBC analysis. In view of the fact that our results on the loss of CD55 are almost significant, it is likely to be so in a more powerful study.
It has been known that the attachment of the GPI-anchored proteins, CD55 and CD59, to plasma membranes via their inositol-phospholipids renders them potentially more displaceable from cell surfaces than conventionally anchored proteins. They are susceptible to cleavage and release by phosphatidyl inositol-specific phospholipase C, an enzyme that is present in mammalian tissues. CD55 and CD59 molecules with GPI anchors containing unacetylated inositol are preferentially lost [22] . If the GPI anchor structure of CD59 on stored RBCs does not differ from that of CD55, a defect in a GPI anchor assembly should affect the expression of both proteins in an equivalent manner. Bütikofer et al. [23] showed that GPI-anchored proteins are redistributed on the surface of human RBCs and preferentially depleted during vesiculation, which is one of the structural changes that occur in storage lesions. Whether the nonphysiological medium of the aging PRBC unit preferentially causes the displacement of an alternatively anchored CD59 (non-GPI-anchored CD59 molecule) form, rendering it more displaceable from the RBC surface, is a question that needs to be investigated in future studies. Interestingly, we have previously shown a similar expression pattern on RBCs from patients with sickle cell disease, in whom CD59 is preferentially lost compared to RBCs from healthy control subjects [24] .
One limitation of this study might be the use of the REDQUANT CD55/CD59 kit. It is an indirect method, and thus the addition of the primary antibody is followed by a polyclonal anti-mouse IgG-FITC antibody. Therefore, conformational changes in the cell surface could render certain antigen sites hidden from the primary antibody or could mean that differing amounts of secondary antibody could bind. This means that the "loss" of antigens could be explained by crenation of the cells on storage. Furthermore, it is likely that RBCs are agglutinated by FITC-conjugated antibodies as this lowers the electronegativity of RBCs that naturally keeps them apart, and, therefore, may prevent further access for the secondary antibody that is potentially a possible cause for the lower signal intensity. Furthermore, the gating strategy used in this study might have underestimated the level of CD55 and CD59 expression. Using an anti-glycophorin antibody in gating might improve RBC isolation for the analysis of CD55 and CD59 expression, although leukodepletion of PRBCs is likely to minimize this effect. In addition, the vitality and properties of RBC stored in a tubing segment might be different from the RBC within the bag, which is a factor that might affect the results of this study.
Conclusion
The results of this study suggest that there is a preferential loss of CD59 expression, but not CD55 expression, on RBCs during blood storage. The significance of the altered CD59 expression during storage is unclear, and its physiological effect in vivo needs further investigation. In view of the results obtained in this study, further studies are needed to clarify their importance in the field of transfusion medicine, including in vitro studies correlating complement-mediated lysis with CD59 expression in stored blood.
